Citations

Clear

1526 citation(s) found for "Sun, C".

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Inaba, Hiroto , Annesley, Colleen , Beck, Jill C., Colace, Susan I. , Dallas, Mari , Kelly, Kara M. , Larrier, Nicole, Mahadeo, Kris M. , Nanda, Ronica H. , Nardi, Valentina , Rodriguez, Vilmarie , Rossoff, Jenna , Schuettpelz, Laura G. , Sun, Jessica , Sun, Weili, Teachey, David T. , Wong, Victor , Yanik, Gregory A. , Johnson-Chilla, Alyse, Ogba, Ndiya , Inaba, Hiroto , DeSantes, Kenneth B , Kitko, Carrie L. , Lacayo, Norman James , Maese, Luke Devon , Silverman, Lewis B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 7, 2020 | Volume: 18 | Issue: 1 | Pages: 81-112

10.6004/jnccn.2020.0001 | PMID 31910389 Get It

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.
Ultrasonic Aspiration for Debulking Infiltrative Masses of the Orbit
Sun, Susan , Stewart, Krista J., Lyford-Pike, Sofía , Garrity, James A., Harrison, Andrew R. , Mokhtarzadeh, Ali , Stewart, Krista

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | December 23, 2019 | Volume: 36 | Issue: 2 | Pages: 198-201

10.1097/iop.0000000000001537 | PMID 31868794 Get It

Purpose: To demonstrate the utility of an ultrasonic aspirator (Sonopet, Stryker Corporation; Kalamazoo, MI) for debulking firm, soft tissue masses of the orbit. Methods: Case series. The ultrasonic aspirator was used to debulk firm, soft tissue masses in 3 cases. The initial patient had a large orbitofacial mass extending to the inferior and lateral orbital apex secondary to IgG4 disease. The second patient had a lacrimal sac adenocarcinoma extending to the medial orbital apex. The third patient had a large orbital mass extending to the apex secondary to granulomatosis with polyangiitis. Results: The ultrasonic aspirator facilitated debulking of infiltrative firm soft tissue masses of the orbit. The device’s ability to emulsify, irrigate, and aspirate, along with its small footprint, facilitated precise sculpting and debulking to an extent which would have been difficult otherwise due to location. Conclusions: The ultrasonic aspirator allows precise sculpting of infiltrative firm soft tissue masses in the orbit and is particularly useful in cases with challenging anatomical access.
Hypoxia‐induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF‐κB
Liu, Limin , Bai, Ming , Liu, Minna , Yang, Zhen , Qian, Qi , Ning, Xiaoxuan , Sun, Shiren , Zhang, Lei , Bai, Ming, Lei, Wei

Mayo Clinic

The FASEB Journal | December 19, 2019 | Volume: 34 | Issue: 2 | Pages: 2554-2567

10.1096/fj.201901950r | PMID 31909536 Get It

Abstract Hypoxia‐induced extracellular matrix (ECM) deposition is an important cause of renal fibrosis that is triggered by unknown mechanisms. Human epididymis secretory protein 4 (HE4) is a newly discovered key molecule that causes ECM deposition. We used the unilateral ureteral obstruction (UUO) mouse model to investigate the expression and mechanisms of HE4 in the pathogenesis of renal fibrosis. Results were confirmed in the HK2 cell line and in human donors of kidney tissue with chronic kidney disease. Hypoxia significantly increased HE4 in renal tubular epithelial cells. HE4 overexpression activated the NF‐κB pathway through the NF‐κB transcription‐activating group P65 by phosphorylation and nuclear translocation. NF‐κB upregulated tissue inhibitor metalloproteinases 1, which may inhibit ECM degradation through inhibition of matrix metallopeptidase 2 activity. Silencing HE4 inhibited hypoxia‐induced ECM deposition and alleviated fibrosis in UUO mice in vivo and blocked NF‐κB activation in vitro. Expression of HE4 in the tubulointerstitium was positively correlated with tubulointerstitial fibrosis in tissue samples from patients with chronic kidney disease. Our results suggest that hypoxia induces renal fibrosis by upregulating HE4 and activating the HIF‐1α/HE4/NF‐κB signaling pathway. Uncovering the molecular mechanisms and function of HE4 overexpression in hypoxia‐induced renal fibrosis will provide important insights into understanding renal fibrosis and antifibrotic strategies.
Whole Exome Sequencing of Highly Aggregated Lung Cancer Families Reveals Linked Loci for Increased Cancer Risk on Chromosomes 12q, 7p, and 4q
Musolf, Anthony M. , Moiz, Bilal A., Sun, Haiming , Pikielny, Claudio W. , Bossé, Yohan , Mandal, Diptasri , Andrade, Mariza de , Gaba, Colette , Li, Yafang , You, Ming , Govindan, Ramaswamy , Wilson, Richard K., Kupert, Elena, Anderson, Marshall W., Schwartz, Ann G. , Pinney, Susan M. , Bailey‐Wilson, Joan E. , de Andrade, Mariza , Wilson, Richard K , Amos, Christopher I , Bossé, Yohan , Pinney, Susan M , Govindan, Ramaswamy , Yang, Ping , Amos, Christopher I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 11, 2019 | Volume: 29 | Issue: 2 | Pages: 434-442

10.1158/1055-9965.epi-19-0887 | PMID 31826912 Get It

Abstract Background: Lung cancer kills more people than any other cancer in the United States. In addition to environmental factors, lung cancer has genetic risk factors as well, though the genetic etiology is still not well understood. We have performed whole exome sequencing on 262 individuals from 28 extended families with a family history of lung cancer. Methods: Parametric genetic linkage analysis was performed on these samples using two distinct analyses—the lung cancer only (LCO) analysis, where only patients with lung cancer were coded as affected, and the all aggregated cancers (AAC) analysis, where other cancers seen in the pedigree were coded as affected. Results: The AAC analysis yielded a genome-wide significant result at rs61943670 in POLR3B at 12q23.3. POLR3B has been implicated somatically in lung cancer, but this germline finding is novel and is a significant expression quantitative trait locus in lung tissue. Interesting genome-wide suggestive haplotypes were also found within individual families, particularly near SSPO at 7p36.1 in one family and a large linked haplotype spanning 4q21.3-28.3 in a different family. The 4q haplotype contains potential causal rare variants in DSPP at 4q22.1 and PTPN13 at 4q21.3. Conclusions: Regions on 12q, 7p, and 4q are linked to increased cancer risk in highly aggregated lung cancer families, 12q across families and 7p and 4q within a single family. POLR3B, SSPO, DSPP, and PTPN13 are currently the best candidate genes. Impact: Functional work on these genes is planned for future studies and if confirmed would lead to potential biomarkers for risk in cancer.
Longitudinal EEG Changes Correlate with Cognitive Measure Deterioration in Parkinson's Disease
Caviness, John N., Hentz, Joseph G. , Belden, Christine M. , Shill, Holly A. , Driver‐Dunckley, Erika , Powell, Jessica, Driver-Dunckley, Erika D., Sabbagh, Marwan Noel , Adler, Charles H.

Mayo Clinic

Journal of Parkinson’s Disease | December 3, 2019 | Volume: 5 | Issue: 1 | Pages: 117-124

10.3233/jpd-140480 | PMID 25420672 Get It

Background: QEEG could provide physiological biomarkers for changes over time in Parkinson's disease (PD) cognitive decline if they track with longitudinal neuropsychological performance. Objective: Our aim was to correlate longitudinal changes in frequency domain quantitative electroencephalography (QEEG) measures with change in neuropsychological performance testing in PD. Methods: 71 PD subjects, not demented at baseline, were studied from the Arizona Study of Aging and Neurodegenerative Disorders cohort. Baseline and follow-up digital EEG from PD subjects were analyzed for QEEG measures of background rhythm frequency and global relative power in delta (2.5–4 Hz), theta (4–8 Hz), alpha (8–13 Hz), and beta (13–30 Hz) bands. Baseline and subsequent evaluation included Mini Mental Status Examination and five other neuropsychological tests that load on cognitive domains known to decline in PD. Pearson coefficient was used to assess correlations. Multiple linear regression modeling was used to assess the effect of variable combinations of QEEG and other measures, including age and PD duration. Results: Changes in delta bandpower showed the highest and most consistent pattern of correlations with longitudinal changes in neuropsychological testing. The highest correlation was between delta bandpower increase and decline in the Rey Auditory-Verbal Learning Test (−0.59:p < 0.001). Delta bandpower was also increased in the incident dementia group compared to non-dementia at followup. Conclusions: 1) Longitudinal change in the QEEG frequency domain measure of delta bandpower correlated best with longitudinal neuropsychological performance change in PD; 2) These results constitute preliminary evidence that delta bandpower may be a suitable biomarker for evaluating PD cognitive deterioration longitudinally.
Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging
Dugger, Brittany N. , Sue, Lucia I., Walker, Douglas G. , Shill, Holly A. , Caviness, John N., Saxon‐LaBelle, Megan, Chiarolanza, Glenn, Mariner, Monica, Henry-Watson, Jonette, Beach, Thomas G. , Dugger, Brittany N , Serrano, Geidy E. , Adler, Charles H. , Sabbagh, Marwan Noel , Hidalgo, Jose

Mayo Clinic

Journal of Parkinson’s Disease | December 3, 2019 | Volume: 2 | Issue: 1 | Pages: 57-65

10.3233/jpd-2012-11073 | PMID 22924088 Get It

Dementia is a frequent complication of Parkinson's disease (PD). About half of PD dementia (PDD) is hypothesized to be due to progression of the underlying Lewy body pathology into limbic regions and the cerebral cortex while the other half is thought to be due to coexistent Alzheimer's disease (AD). Clinically, however, these are indistinguishable. The spread of amyloid plaques to the striatum has been reported to be a sensitive and specific indicator of dementia due to AD. The purpose of the present study was to determine if the presence of striatal plaques might also be a useful indicator of the presence of diagnostic levels of AD pathology within PD subjects. We analyzed neuropathologically-confirmed cases of PD without dementia (PDND, N = 31), PDD without AD (PDD, N = 31) and PD with dementia meeting clinicopathological criteria for AD (PDAD, N = 40). The minimum diagnostic criterion for AD was defined as including a clinical history of dementia, moderate or frequent CERAD cortical neuritic plaque density and Braak neurofibrillary stage III-VI. Striatal amyloid plaque densities were determined using Campbell-Switzer and Thioflavine S stains. Striatal plaque densities were significantly higher in PDAD compared to PDD (p < 0.001). The presence of striatal plaques was approximately 80% sensitive and 80% specific for predicting AD. In comparison, the presence of cerebral cortex plaques alone was highly sensitive (100%) but had poor specificity (48% to 55%). The results suggest that striatal amyloid imaging may be clinically useful for making the distinction between PDD and PDAD.
Human synoviocyte lubricin and bovine synovial fluid lubricin equally improve gliding resistance in a canine model in vitro
Kohn, Mark D. , Sun, Yu-Long, Zhao, Chunfeng , Thoreson, Andrew R. , Jay, Gregory D. , An, Kai‐Nan , Amadio, Peter C.

Mayo Clinic

Bio-Medical Materials and Engineering | December 2, 2019 | Volume: 21 | Issue: 5-6 | Pages: 281-289

10.3233/bme-2012-0676 | PMID 22561248 Get It

Tribute to Paul M. Vanhoutte, MD, PhD (1940–2019)
Baretella, Oliver , Blaise, Gilbert, Bond, Richard A. , Cai, Yin , Chan, C K, Chataigneau, Thierry, Chen, M., Chen, Hui , Cheng, Yanhua, Clément, Denis, Cohen, Richard A. , Collis, Michael J., Detremmerie, Charlotte Marie Simonne, Félétou, Michel, Flavahan, Nicolas, Gao, Yuansheng, Guo, Yumeng , Hoeffner, U., Houston, Donald S., Huang, Ianto Boscheng, Huang, Yü , Iliano, Stephane, Junquéro, Didier, Katušić, Zvonimir S. , Komori, Kimihiro , Lee, Mary Y. K. , Leung, Susan W.S. , Li, Zhuo-ming, Liang, Sophie Chaofan, Liu, J, Lüscher, Thomas F. , Michel, Frederic, Miller, Virginia M. , Mombouli, Jean-Vivien, Morrison, Keith , Muldoon, Sheila M., O’Rourke, Steve, Perrault, Louis P. , Quignard, Jean‐François , Rusch, Nancy J. , Sánchez‐Ferrer, Carlos F. , Shen, Kaikai , Shi, Yi , Song, Erfei , Sun, Kiwi W.Y., Tang, Eva Hoi Ching, Tuncer, Meral , Ende, Romana van den, Vedernikov, Yuri P., Verbeuren, Tony J., Webb, Clinton, Wong, Kenneth H.K., Xu, Cheng , Yang, Kangmin , Zellers, Thomas M. , Zhao, Yingzi , Zou, Qian , fellows, on behalf of Professor Paul M. Vanhoutte’s former, Boulanger, Chantal M. , Collis, Michael, Danser, A.H. Jan , Mey, Jo G. R. De , Duprez, Daniel , Huang, Ianto Bosheng , Michel, Frederic, Schini‐Kerth, Valérie B. , Shi, Yi, Taddei, Stefano , Tang, Eva H.C., Weigert, André Luiz Loureiro , Wong, Kenneth K. H., Ying, Fan, Shimokawa, Hiroaki , fellows, on behalf of Professor Paul M. Vanhoutte’s former

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | November 26, 2019 | Volume: 39 | Issue: 12 | Pages: 2445-2447

10.1161/atvbaha.119.313461 | PMID 31770032 Get It

Molecular Profiles of Matched Primary and Metastatic Tumor Samples Support a Linear Evolutionary Model of Breast Cancer
Chen, Runpu , Goodison, Steve , Sun, Yijun

Mayo Clinic

Cancer Research | November 19, 2019 | Volume: 80 | Issue: 2 | Pages: 170-174

10.1158/0008-5472.can-19-2296 | PMID 31744819 Get It

Abstract The interpretation of accumulating genomic data with respect to tumor evolution and cancer progression requires integrated models. We developed a computational approach that enables the construction of disease progression models using static sample data. Application to breast cancer data revealed a linear, branching evolutionary model with two distinct trajectories for malignant progression. Here, we used the progression model as a foundation to investigate the relationships between matched primary and metastasis breast tumor samples. Mapping paired data onto the model confirmed that molecular breast cancer subtypes can shift during progression and supported directional tumor evolution through luminal subtypes to increasingly malignant states. Cancer progression modeling through the analysis of available static samples represents a promising breakthrough. Further refinement of a roadmap of breast cancer progression will facilitate the development of improved cancer diagnostics, prognostics, and targeted therapeutics. Significance: Analysis of matched primary and metastatic tumor samples supports a unidirectional, linear cancer evolution process and sheds light on longstanding issues regarding the origins of molecular subtypes and their progression relationships.